-rafenib
A RAF kinase inhibitor, blocking a link in the MAPK growth-signal chain; used in melanoma and other cancers with BRAF mutations.
- Drugs ending in -rafenib: 17
- Approved somewhere: 6
- With a US drug page: 6
- Stem
- -rafenib
- Class
- Drugs that block RAF kinases, like sorafenib
- Most common targets
- BRAF (7), RAF1 (2), KIT (2), Vascular endothelial growth factor receptor (2), RET (2), RAF serine/threonine protein kinase (2), ABL1 (1), FGFR1 (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -rafenib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Dabrafenib | Approved | BRAF | Serine/threonine-protein kinase B-raf inhibitor |
| Encorafenib | Approved | BRAF | Serine/threonine-protein kinase B-raf inhibitor |
| Regorafenib | Approved | ABL1, RAF1, KIT, FGFR1 and 11 more | Tyrosine-protein kinase ABL inhibitor |
| Sorafenib | Approved | RAF1, PDGFRB, KIT, FLT3 and 3 more | Serine/threonine-protein kinase RAF inhibitor |
| Tovorafenib | Approved | RAF serine/threonine protein kinase | RAF serine/threonine protein kinase inhibitor |
| Vemurafenib | Approved | BRAF | Serine/threonine-protein kinase B-raf inhibitor |
| Naporafenib | Phase 3 | BRAF, RAF1 | B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor |
| Belvarafenib | Phase 2 | RAF serine/threonine protein kinase | RAF serine/threonine protein kinase inhibitor |
| Brimarafenib | Phase 2 | — | — |
| Exarafenib | Phase 2 | — | — |
| Flezurafenib | Phase 2 | — | — |
| Mosperafenib | Phase 2 | — | — |
| Plixorafenib | Phase 2 | BRAF | Serine/threonine-protein kinase B-raf inhibitor |
| Uplarafenib | Phase 2 | — | — |
| Claturafenib | Phase 1 | — | — |
| Lifirafenib | Phase 1 | BRAF | Serine/threonine-protein kinase B-raf inhibitor |
| Tinlorafenib | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO